Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · June 03, 2023

Sintilimab Plus Chemotherapy for EGFR-Mutated Non-Squamous NSCLC With Disease Progression After EGFR TKI Therapy

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2023 May 05;[EPub Ahead of Print], S Lu, L Wu, H Jian, Y Cheng, Q Wang, J Fang, Z Wang, Y Hu, L Han, M Sun, L Miao, C Ding, J Cui, K Wang, B Li, X Li, F Ye, A Liu, Y Pan, S Cang, H Zhou, X Sun, Y Shen, S Wang, W Zhang, Y He

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading